Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • About the Observatory
      • Our activities
      • Our topics
      • Our partners and networks
      • Digital library
      • Data desk
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Patent filings
            • Go back
            • Overview
            • Detailed methodology
            • Archive
          • Online Services
          • Patent information
            • Go back
            • Overview
            • Innovation process survey
          • Customer services
          • Filing services
          • Website
          • Survey on electronic invoicing
          • Companies innovating in clean and sustainable technologies
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
        • Culture Space A&T 5-10
          • Go back
          • Catalyst lab & Deep vision
            • Go back
            • aqua_forensic
            • LIMINAL
            • MaterialLab
            • Perfect Sleep
            • Proof of Work
            • TerraPort
            • Unfinished Sculpture - Captives #1
            • Deep vision – immersive exhibition
          • The European Patent Journey
          • Sustaining life. Art in the climate emergency
          • Next generation statements
          • Open storage
          • Cosmic bar
        • Lange Nacht 2023
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • About the Observatory
      • Our activities
      • Our topics
      • Our partners and networks
      • Digital library
      • Data desk
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t161535eu1
  1. Home
  2. T 1535/16 (Compositions comprising fentanyl / KYOWA KIRIN) 20-09-2021
Facebook X Linkedin Email

T 1535/16 (Compositions comprising fentanyl / KYOWA KIRIN) 20-09-2021

European Case Law Identifier
ECLI:EP:BA:2021:T153516.20210920
Date of decision
20 September 2021
Case number
T 1535/16
Petition for review of
-
Application number
04701381.8
IPC class
A61K 9/00
A61K 31/4468
A61P 25/04
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 389.22 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

PHARMACEUTICAL COMPOSITIONS COMPRISING FENTANYL FOR INTRANASAL DELIVERY

Applicant name
Kyowa Kirin Services Ltd
Opponent name
Generics [UK] Limited
Board
3.3.07
Headnote
-
Relevant legal provisions
European Patent Convention Art 100(c)
European Patent Convention Art 100(a)
European Patent Convention Art 56
Keywords

Amendments - allowable (yes)

Inventive step - (yes)

Catchword
-
Cited decisions
T 0985/06
Citing decisions
-

I. European patent 1 635 783 (hereinafter "the patent") was granted on the basis of 23 claims. The independent claims of the patent as granted read as follows:

"1. A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof, which comprises an aqueous solution of

(i) fentanyl or a pharmaceutically acceptable salt thereof;

(ii) a pectin having a degree of esterification (DE value) of less than 30%;

(iii) a non-metal ion osmolality adjusting agent selected from polyhydric alcohols and sugars

provided that the composition is substantially free of divalent metal ions; and the composition has an osmolality of from 0.1 to 1.0 osmol/kg."

"17. A composition according to any one of the preceding claims for use in the treatment or prevention of acute or chronic pain."

"18. The use of a pectin having a degree of esterification (DE value) of less than 30% and a non-metal ion osmolality adjusting agent selected from polyhydric alcohols and sugars in the manufacture of a medicament for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to a patient in need thereof, which medicament is substantially free of divalent metal ions and has an osmolality of from 0.1 to 1.0 osmol/kg."

"23. A process for preparing a composition according to any one of claims 1 to 17, which process comprises mixing fentanyl or a pharmaceutically acceptable salt thereof with the pectin and the non-metal ion osmolality adjusting agent in water."

II. An opposition was filed against the patent on the grounds that its subject-matter lacked novelty and inventive step, it was not sufficiently disclosed and it extended beyond the content of the application as originally filed.

III. The opposition division took the interlocutory decision that, on the basis of auxiliary request 3, the patent and the invention to which it relates met the requirements of the EPC. Auxiliary request 3 was filed during the oral proceedings held on 17 November 2015 and contained 21 claims.

IV. The decision of the opposition division, posted on 2 May 2016, cited inter alia the following documents:

D2: US 6,432,440

D3: WO 02/00195

D8: Gennaro, Alfonso R, "Remington's Pharmaceutical Sciences" Mack Publishing Company, 1985, Ed 17**(th)

D10: Christrup et al, "Pharmacokinetics, Efficacy, and Tolerability of Fentanyl Following Intranasal Versus Intravenous Administration in Adults Undergoing Third-Molar Extraction; A Randomised, Double-Blind, Double-Dummy, TwoWay, Crossover Study", Clinical Therapeutics, Vol. 30, No. 3, 2008, P469-481

D11: Fisher et al, "Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188", International Journal of Clinical Pharmacology and Therapeutics, Vol. 48, No. 2/2010, pages 138-143

D12: Annex 2, filed by the Proprietor with letter dated 11.01.2010

D13: Annex 3, filed by the Proprietor with letter dated 11.01.2010

D14: Annex A, filed by the Proprietor with letter dated 05.09.2012

D15: Annex B, filed by the Proprietor with letter dated 05.09.2012

D16: An Introduction to Pectins: Structure and Properties; James N. BeMifler, pp. 2-12; in: Chemistry and Function of Pectins; Editor(s): Marshall L. Fishman, Joseph J. Jen, Volume 310, Publication Date (Print): June 05, 1986, American Chemical Society

D17: WO 93/21903

V. The opposition division decided in particular as follows:

(a) The wording used for the amended feature defining the degree of esterification of the pectin, namely "less than 30%", implied that the specific value of 30% was excluded. This exclusion did not have a basis in the original application. Claim 1 of the patent as granted did consequently not meet the requirements of Article 123(2) EPC.

(b) The examples of the patent in suit did provide sufficient information to carry out the invention. In the absence of evidence to the contrary, the first auxiliary request thus met the requirements of Article 83 EPC.

(c) Several selections would have to be performed within the disclosure of D2 to arrive at the claimed subject-matter. Furthermore, the claimed osmolality was not explicitly disclosed in D2. The first auxiliary request thus met the requirements of Article 54 EPC.

(d) Starting from D2 as the closest prior art the solution offered by auxiliary request 1 to the problem of providing an alternative intranasal fentanyl composition was not obvious. The skilled person would not have found in D2 alone or in combination with D17, D16 or D3 any incentive to the specific combination of features of the first auxiliary request. The first auxiliary request thus met the requirements of Article 56 EPC.

(e) However, claim 14 of auxiliary requests 1 and 2 did not meet the requirements of Article 123(2) EPC.

(f) The third auxiliary request met the requirements of the EPC.

VI. Both the patent proprietor (appellant - patent proprietor) and the opponent (appellant - opponent) lodged an appeal against the decision of the opposition division.

VII. With its statement setting out the grounds of appeal the appellant - patent proprietor defended its case on the basis of the patent as granted as the main request, and on the basis of auxiliary requests 1, 2, 2A and 3 filed therewith.

VIII. On 13 April 2021, a communication pursuant to Article 15(1) RPBA 2020 was issued by the Board. In said communication the Board provided inter alia its preliminary opinion that:

(a) the amendments performed in the patent in suit, in particular the modification of the degree of esterification (DE) as being "less than 30%", met the requirements of Article 123(2) EPC, and

(b) regarding inventive step, the selection of a DE of less than 30% for the pectin in order to achieve advantageous release profile of fentanyl did not appear to be suggested in any of the cited prior art documents.

IX. By letter dated 30 July 2021, the appellant - opponent announced that it would not be attending the oral proceedings scheduled to take place before the Board of Appeal on 5 October 2021.

X. By letter dated 10 August 2021, the appellant - patent proprietor announced the conditional withdrawal of its request for oral proceedings, should the Board maintain the patent as granted (main request).

XI. The oral proceedings were cancelled.

XII. The appellant - patent proprietor requested that the decision under appeal be set aside and the patent be maintained as granted (main request), or that the patent be maintained on the basis of one of the auxiliary requests 1, 2, 2A and 3 submitted with the statement setting out the grounds of appeal, wherein auxiliary requests 1, 2 and 3 corresponded to auxiliary requests 1, 2 and 3 filed during the first instance oral proceedings held on 17 November 2015.

XIII. The appellant - opponent requested that the decision under appeal be set aside and that the patent be revoked.

XIV. The arguments of the appellant - patent proprietor, as far as relevant for the present decision, can be summarised as follows:

(a) The subject-matter of the claims of the main request did not extend beyond the content of the original application. In particular, in line with T 1170/02, the feature "less than 30%" was directly and unambiguously derivable from the original application, especially from original page 6 lines 9-12 and lines 21-24. The remaining amendments also found a basis in the original application (see in particular original page 3 lines 18-27, original page 12 lines 10-16 and original page 11 line 21).

(b) The closest prior art was D2. D2 did not disclose a composition being aqueous, having an osmolality of 0.1 to 1.0 osmol/kg and containing each of the following elements:

(i) fentanyl,

(ii) a pectin with a degree of esterification (DE) of from 5 to 25%, and

(iii) a non-metal ion osmolality agent selected from polyhydric alcohols and sugars.

The problem to be solved resided in the provision of a composition for the intranasal administration of fentanyl in a practical dose volume that provided rapid absorption in combination with a lower peak plasma concentration than that provided using a simple aqueous solution. As substantiated by D12-D13, the use of a pectin having a DE below 30% led to a modification of the release profile, which would allow reducing the risk of dangerous side-effects while still achieving a rapid pain relief. This effect was neither suggested in D2 nor in the further documents cited by the appellant - opponent. The main request thus met the requirements of Article 56 EPC.

XV. The arguments of the appellant - opponent, as far as relevant for the present decision, can be summarised as follows:

(a) Claims 1 and 18 of the main request infringed Article 123(2) EPC, for the following reasons:

- The feature regarding the peak plasma concentration represented an essential feature of the described composition for intranasal delivery of fentanyl (see original abstract, original claim 1, original page 5 first paragraph, original page 14 second and third paragraph and paragraph bridging pages 3-4). Its deletion thus extended the claimed subject-matter beyond the originally disclosed content.

- Furthermore, the presently claimed combination of features (specific DE, limitation of the additive to pectin, specific non-metal ion osmolality adjusting agent and specific osmolality) was not originally disclosed. The respective specific features were selected and combined in an arbitrary manner.

- Finally, the feature "a pectin having a degree of esterification (DE value) of less than 30%" was not originally disclosed because the upper value of said range was not individually disclosed. The present situation was similar to the one underlying T 985/06. The originally disclosed ranges ("less than 35%" and "7 to 30%"), despite encompassing any value therein, did indeed not disclose any such value individually.

(b) The closest prior art was D2. The opposed patent aimed at providing an alternative nasal spray containing fentanyl without any unexpected effects. The features allegedly constituting distinguishing features versus D2 were generally disclosed in D2, as follows:

(i) Fentanyl was mentioned in column 7 line 25,

(ii) a pectin with a DE falling under the presently claimed range was described (see reference to Slendid which has a DE of 10%),

(iii) polyhydric alcohols and sugars, generally known as non-metal ion osmolality agents, were suggested (see reference to sucrose or non-ionic polysaccharides in column 8 third paragraph and reference to a composition free of divalent metal ions in column 5 lines 11-13 and 31-39 together with D16-D17, which provided further indications towards the osmolality adjusting properties of such components) and

(iv) an aqueous solution was described (see column 5, second paragraph and column 6, 2nd paragraph). Furthermore the provision of an isotonic composition, i.e. a composition having an osmolality within the presently claimed range, constituted a standard approach in the field as revealed by D8. The subject-matter of claim 1 of the main request was thus not inventive in the light of D2 together with the general knowledge in the field as evidenced by D8, D16 and D17. Moreover the subject-matter of claim 1 was also rendered obvious when combining the teachings of D2 and D3. The latter indeed described the treatment of pain of the mucous nasal membrane (page 6 lines 21-22) using muco-adhesive pectin (page 7 line 9) and iso-osmotic agents such as dextrose (see page 14 lines 24-27). Hence, the main request did not meet the requirements of Article 56 EPC.

Main request - Patent as granted

2. Amendments

2.1 Claim 1 of the main request is based on original claim 1 wherein inter alia:

(a) a specific degree of esterification (DE) has been indicated for the pectin, namely "less than 30%",

(b) the subject-matter has been limited to the alternative relating to the presence of a pectin,

(c) the presence of a non-metal ion osmolality adjusting agent selected from polyhydric alcohols and sugars has been added,

(d) the osmolality of the composition has been specified, namely as being from 0.1 to 1.0 osmol/ kg, and

(e) the functional feature relating to the peak plasma concentration has been deleted.

2.2 As underlined by the appellant - patent proprietor, compositions not limited by the functional feature mentioned above under (e) are generally described as representing the subject-matter of the invention on original page 3 lines 18-27. Furthermore, the Board observes that the paragraph following this passage (paragraph bridging pages 3 and 4, as cited by the appellant - opponent) actually indicates that the described compositions do fulfill said functional feature. Contrary to the opinion of the appellant - opponent, the Board accordingly considers that the skilled person would not have understood said paragraphs in such a way that only parts of the structurally defined compositions fulfill said functional feature. The skilled person would rather have understood that all the disclosed compositions, i.e. including those defined by the structural features of amended claim 1, achieve the originally claimed peak plasma concentration, thus rendering said functional definition non-essential.

2.3 The features (c) and (d) find support on original page 12 lines 10-16 and original page 11 line 21, respectively. These passages describe the corresponding features in a general way. As argued by the appellant - patent proprietor, the skilled person would have understood that these features apply to all the disclosed compositions. Furthermore, the Board observes that the alternative relating to pectins (see feature (b)) is supported by original claim 1 and even individualised in original claim 5. The argument of the appellant - opponent that the combination of features of claim 1 of the main request would not be disclosed as such in the original application is therefore not convincing.

2.4 Regarding feature (a), the ranges "less than 35%" and preferably (inter alia) "7 to 30%" are disclosed on original page 6 lines 9-12. The appellant - opponent argued that the new upper limit of the range, namely "less than 30%", cannot be directly and unambiguously derived from the application as filed because the disclosed ranges ("less than 35%" or "7 to 30%"), despite encompassing any value therein, do not disclose any such value individually. The Board finds that, in the present case, such an approach appears overly literal. Said percentage refers to the degree of esterification (DE) of a heterogenous polymeric material (see original description page 5 lines 10-14), which according to common general knowledge, actually corresponds to an average value determined for a sample of said heterogenous material by intrinsically uncertain analytical chemistry methods. The Board therefore considers that no technical difference can be made between a sample having a DE very close to 30% and a sample having a DE at 30%. This is confirmed by the use in the original application of exact values or "about" values to refer to the same ranges (see e.g. original description page 6 lines 9-12 and line 24). Accordingly, the new upper limit ("less than 30%") does not introduce any new technical information compared to the originally explicitly disclosed ranges and values, including the value of 30%. The Board consequently considers that the above-mentioned feature (a) is directly and unambiguously derivable from the original application taken as a whole. This opinion was already provided in the preliminary opinion of the Board issued on 13 April 2021 and the appellant - opponent did not provide any further argument in reply thereto. The Board therefore confirms its opinion. Regarding T 985/06 cited by the appellant - opponent in its reply to the statement of grounds of appeal, the Board notes that in the case underlying said decision the range concerned a molar ratio (i.e. a different physico-chemical value). In said earlier case, it was considered that the upper-end value of the newly claimed range could actually be distinguished from the one originally claimed. For the reasons developed above, the Board is of the opinion that this is not possible in the technical circumstances of the present case. The conclusion reached in T 985/06 cannot therefore be "directly applied to the present case" as argued by the appellant - opponent in its reply.

2.5 The same conclusion applies to claim 18 of the main request, in so far as it contains the same features as claim 1. The appellant - opponent did not object to the remaining claims of the main request. Claims 2-17 and 19-23 of the main request are further based on the original claims and description.

2.6 Accordingly the ground of opposition under Article 100(c) EPC does not prejudice the maintenance of the granted patent (main request).

3. Sufficiency of disclosure and novelty

The appellant - opponent did not pursue at the appeal stage its objections under Article 100(b) EPC and Article 100(a) EPC in combination with Article 54 EPC. In line with the conclusions of the opposition division regarding auxiliary request 1, which apply mutatis mutandis to the main request, the Board considers that the grounds of opposition under Article 100(b) EPC and Article 100(a) EPC in combination with Article 54 EPC do not prejudice the maintenance of the granted patent (main request).

4. Inventive step

4.1 Closest prior art

4.1.1 The patent in suit relates to an aqueous intranasal fentanyl composition comprising a pectin with a specific low degree of esterification (namely less than 30%), which is useful in the treatment of pain. The composition further contains a non-metal ion osmolality adjusting agent selected from polyhydric alcohols and sugars and has an osmolality of 0.1 to 1.0 osmol/kg. The purpose of the invention is to provide a liquid composition which forms a gel once administered through the nasal route and provides rapid absorption in combination with a lower peak plasma concentration and optionally an extended plasma-concentration time profile (see Bl paragraph [0019]). The composition is defined as being substantially free of divalent metal ions in order to avoid gelation during storage (i.e. prior to administration).

4.1.2 In accordance with both parties' submissions, D2 is considered to represent the closest prior art. D2 discloses liquid pharmaceutical compositions for administration to the mucosal surface, in particular the nasal mucous. Said compositions comprise an aqueous carrier, a therapeutic agent and a pectin having a degree of esterification of less than 50% (see for example claim 1). As identified by the appellant - opponent, D2 further discloses several features of the present claims:

- fentanyl is listed as possible therapeutic agent on column 7 line 25,

- Slendid Type 100, a pectin having a DE of the order of 10%, is mentioned among other useful pectins on column 6 lines 5-12, and

- the addition of sugars or non-ionic polysaccharides as gelation aid is disclosed on column 8 lines 15-18.

The purpose of the teaching in D2 is to provide a liquid pharmaceutical composition which gels at the site of application (see column 4 lines 43-48) and allows the retention of the therapeutic agent for a longer period (see column 6 lines 49-55).

4.2 Distinguishing feature

D2 very generally describes all the components of the present compositions. However, D2 does not disclose any preferred embodiment or specific example of a composition comprising the present combination of features (specific therapeutic agent, specific DE for the pectin and specific osmolality-adjusting agent). In particular, D2 does not describe any specific example of a fentanyl composition, letting alone a fentanyl composition containing pectin having a DE value of less than 30%. Furthermore, D2 does not provide osmolality values for the disclosed compositions.

4.3 Technical effect and objective technical problem

4.3.1 The data reported in D12-D13 relate to a comparison between compositions with fentanyl and pectins having a DE below 30% and compositions differing therefrom only in that the pectins have a DE above 30%. Such a comparison is therefore suitable to substantiate an effect linked to the specific choice of the DE according to the present claim 1 in combination with fentanyl, which constitutes a distinguishing feature versus the closest prior art D2. These data reveal that compositions containing a pectin with a DE below 30% show a higher gel strength (see table on page 2 of D13) as well as a lower immediate release followed by a slow controlled release (see figure 2 of D12 and the figure of D13). It appears further credible, as mentioned by the appellant - patent proprietor, that this release profile may reduce undesirable side-effects linked to high initial absorption rates.

4.3.2 In this context, the appellant - opponent disputed the presence of any particular effect by merely referring to the first instance decision, in which it was assumed that no technical effect was present without discussing the data provided in D12-D13. In the absence of specific arguments with respect to data provided in D12-D13, the presence of the effect as detailed under point 4.3.1, i.e. an advantageous release profile of fentanyl, is considered as credibly substantiated.

4.3.3 For the sake of completeness, the Board notes that the documents D10-D11, D14 and D15 further cited by the appellant - patent proprietor in this context are not suitable to substantiate a technical effect directly linked to a distinguishing feature versus the closest prior art D2. D14 provides indeed a comparison with a composition containing a different therapeutic agent than fentanyl and D10, D11 and D15 relate to features which do not constitute a distinguishing feature towards D2.

4.3.4 The Board consequently considers that the objective technical problem to be solved, starting from D2, consists in the provision of further intranasal compositions comprising fentanyl and pectin and having an advantageous release profile.

4.4 Obviousness of the solution

The Board observes that a pectin according to the present claims is generally disclosed and used in the examples of D2 together with therapeutic agents different from fentanyl (see Slendid 100 having a DE of around 10%). According to example 4 and figure 2 of D2, adding said pectin to an intranasal formulation of fexofenadine drastically modifies the drug release profile thereof (no immediate release any more when using pectin). As brought forward by the appellant - patent proprietor, the drug release profile obtained in the case of fexofenadine in D2 is however different from the one desired in the case of fentanyl (still some immediate release needed to ensure fast pain relief). Furthermore, there does not appear to be an indication in D2 that the value of 30% for the DE of pectin would have a particular influence on the release profile of fentanyl. The present release profile of fentanyl when using a pectin having a DE of less than 30% would not have been expected in view of D2. Contrary to the opinion of the appellant - opponent, there is consequently no suggestion in D2 to use Slendid in combination with fentanyl so as to achieve the present release profile. None of the further documents cited by the appellant - opponent (namely D3, D8, D16 and D17) provides a hint to the selection of this particular value of DE for the pectin so as to achieve a lower Cmax and a subsequent plateauing release of fentanyl. D3 generally mentions fentanyl as suitable therapeutic agent and pectin as useful muco-adhesive. D3 does however not disclose a composition comprising both fentanyl and a pectin having the present DE, let alone the effect of said pectin on the release profile of fentanyl. D8 relates neither to fentanyl nor to a pectin according to the present claims. D16, which is a review on pectins, teaches that mono- or multivalent cations have an influence on the viscosity of pectins depending on the DE value of the pectin. However D16 does not disclose any specific value of DE. Finally D17 concerns ophthalmic compositions which contain neither fentanyl nor a pectin. The Board concludes therefore that the selection of a DE of less than 30% for the pectin in order to achieve an advantageous release profile of fentanyl (i.e. providing some immediate pain relief while reducing the risk of undesirable side effects) is not suggested in any of the cited prior art documents.

4.5 Accordingly, the ground of opposition under Article 100(a) EPC in combination with Article 56 EPC does not prejudice the maintenance of the granted patent (main request).

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is maintained as granted.

Footer - Service & support
  • Service & support
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Forums
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility